JAK1 and uveitis: Filgotinib (Jyseleca; Galapagos NV, Mechelen, Belgium) a preferential JAK1 inhibitor, demonstrated efficacy in reducing the risk of uveitis flare by week six of therapy in a Phase II randomised, placebo-controlled trial [18].